Novartis CEO thinks 2nd health lockdown unlikely, as Q3 sales stabiliseNovartis’ pharmaceutical sales recovered in the third quarter of this year after an earlier COVID-19 decline, as new Share XNovartis CEO thinks 2nd health lockdown unlikely, as Q3 sales stabilisehttps://pharmaphorum.com/news/novartis-ceo-thinks-2nd-health-lockdown-unlikely-as-q3-sales-stabilise/
Purdue to pay $8.3bn after admitting criminal charges in opioid caseAfter years of legal wrangling, Purdue Pharma has agreed a deal to resolve litigation about its role in Share XPurdue to pay $8.3bn after admitting criminal charges in opioid casehttps://pharmaphorum.com/news/purdue-to-pay-8-3bn-after-admitting-criminal-charges-in-opioid-case/
FDA grants full approval for Roche/AbbVie’s Venclexta in AML combination therapiesCombination therapies involving Roche and AbbVie’s cancer drug Venclexta have been formally approved by the FDA in acute Share XFDA grants full approval for Roche/AbbVie’s Venclexta in AML combination therapieshttps://pharmaphorum.com/news/fda-grants-full-approval-for-roche-abbvies-venclexta-in-aml-combination-therapies/
10 Tips for Digital Asset Management SuccessGiven the recent rise in digital engagement and the drastic increase in digital content, it’s now essential that Share X10 Tips for Digital Asset Management Successhttps://pharmaphorum.com/whitepapers/10-tips-for-digital-asset-management-success/
Time to change the channel? The future for customer engagement modelsSarah Rickwood delves into IQVIA data to find out exactly how pharma’s HCP engagement has changed over COVID-19, Share XTime to change the channel? The future for customer engagement modelshttps://pharmaphorum.com/sales-marketing/time-to-change-the-channel-the-future-for-customer-engagement-models/
Accelerating the digital approval processThe boom in digital tech over COVID means that pharma can move faster than ever – but the Share XAccelerating the digital approval processhttps://pharmaphorum.com/views-analysis-sales-marketing/accelerating-the-digital-approval-process/
How to optimise pharma’s digital HCP engagementPharmaceutical companies face a ‘digital imperative’ to engage with healthcare professionals through their preferred mix of channels if Share XHow to optimise pharma’s digital HCP engagementhttps://pharmaphorum.com/debates-insight-sales-marketing/how-to-optimise-pharmas-digital-hcp-engagement/
Ensuring delivery of healthcare professional educationPharma companies always need to know they can get the right information to the right people at the Share XEnsuring delivery of healthcare professional educationhttps://pharmaphorum.com/debates-insight-sales-marketing/ensuring-delivery-of-healthcare-professional-education/
Good data supports pharma sales reps to drive lead generationAllow pharma sales reps to focus on the job in hand by making sure they have access to Share XGood data supports pharma sales reps to drive lead generationhttps://pharmaphorum.com/sales-marketing/good-data-supports-pharma-sales-reps-to-drive-lead-generation/
The COVID-19 Effect: How Pharma Can Adapt to the Evolving Patient ExperienceVirtual event highlighting the critical patient POV Share XThe COVID-19 Effect: How Pharma Can Adapt to the Evolving Patient Experiencehttps://pharmaphorum.com/events/the-covid-19-effect-how-pharma-can-adapt-to-the-evolving-patient-experience/
KOL ValidationKOL LANDSCAPE Share XKOL Validationhttps://pharmaphorum.com/partner-content/kol-validation/
Fishawack Health, a new breed of global commercialization partnerFishawack Health has reorganized business operations as a leading global commercialization partner for the life-sciences industry. This is Share XFishawack Health, a new breed of global commercialization partnerhttps://pharmaphorum.com/partner-content/fishawack-health-a-new-breed-of-global-commercialization-partner/
